Sent by email to: [xx.xxx@uclh.nhs.uk](mailto:xx.xxx@uclh.nhs.uk); [xx.xxx@gosh.nhs.uk](mailto:xx.xxx@gosh.nhs.uk)

xx xxx xxx and xx xxx xxx

On behalf of the British Inherited Metabolic Disease Group

31 March 2017

Dear xx xxx and xx xxx

**Final Evaluation Determination: Sebelipase alfa for treating lysosomal acid lipase deficiency (LAL D)**

Thank you for xx xxx email of 24 March to xxx xxx. I note that you have no further comments to make in response to my letter of 9 March and therefore confirm that the appeal points submitted in your letter of 27 February on behalf of the BIMDG are not valid. However, I also note that your main intention was to support the detailed appeal made by the four paediatric units which will go forward to an oral hearing on 25 April and will ensure that point is logged in the appeal papers*.*

Yours sincerely

Andy McKeon

Vice-Chair

National Institute for Health and Care Excellence